We report two cases of systemic lupus erythematosus (SLE) complicated with colonic ulcerations. One patient was successfully cured by steroid therapy, while the other did not respond to steroid but oral mesalazine was effective. Systemic lupus erythematosus is frequently accompanied by gastrointestinal symptoms, but colonic lesions are quite rare, and the regular treatment is not fixed yet. 
Introduction
Abdominal pain and diarrhea are frequent gastrointestinal manifestations of active systemic lupus erythematosus (SLE) (1) . However, gastrointestinal lupus vasculitis is a rare complication that may affect every part of the gastrointestinal tract, leading to further complications, such as vasculitic enterocolitis. Vasculitis of the bowel may in turn lead to ulceration, hemorrhage, perforation or infarction (2) . Steroid therapy is considered the preferred treatment for gastrointestinal vasculitis associated with increased SLE activity.
We report herein two cases of SLE complicated by ulcerative lesions in the rectum and sigmoid colon. Steroid therapy was effective in one case, but drug resistance necessitated use of an alternate treatment strategy in the other case. We review the literature pertaining to colonic ulcerative lesions as complications of SLE, and discuss possible treatment options in such cases.
Case Report

Patient 1
A 48-year-old woman with a history of SLE was admitted to our hospital in September 2001, because of bloody stool accompanied by abdominal pain, and sensory disorder in her left lower leg. Endoscopic examination revealed a giant ulcerative lesion in her rectum. Details of the patient's clinical course are shown in Fig. 1 .
In 1981, at the age of 28, the patient developed facial erythema and persistent fever. She was diagnosed with SLE on the basis of findings of "butterfly" erythema, biological false-positive reactions in a serological test for syphilis, cellular casts in the urine, and pleuritis/pericarditis. She received steroid therapy, followed by maintenance therapy with oral-prednisolone at 10 mg/day. In March 2001, she experienced feelings of incomplete defecation. At the same time, her anti-DNA antibody levels gradually increased and her complement titers decreased, so the oral prednisolone was increased to 20 mg/day. In early August, she developed a sensory disorder in her left lower extremity and began to experience abdominal pain at defecation. In early September, bloody stool appeared twice, and endoscopic examination revealed an irregularly shaped ulcerative lesion with a punched-out margin in the upper rectum (Rs to Ra), which was pathologically diagnosed as erosive proctitis and ulceration (Fig. 2) . Thus, the patient was admitted to our department in late September for detailed examination and therapy.
On the day of admission, the patient was afebrile with normal vital signs. Physical examination revealed mild tenderness of the middle lower abdomen but no peritoneal signs; other results were essentially normal. Neurological ex-amination disclosed sensory disorders in the left leg and right posterior thigh, and a neuro-conduction study revealed slowed motor conduction velocity in both peroneal nerves, i.e., mononeuropathy multiplex compatible with vasculitic neuropathy.
Laboratory data obtained upon admission are shown in Table 1 . The complete blood cell count (CBC) revealed mild anemia, but there was no leukocytosis. The erythrocyte sedimentation rate (ESR) was moderately elevated, and the Creactive protein (CRP) test was slightly positive. Results of the routine blood chemistry and coagulo-fibrinolytic tests were essentially normal. Results of urinalysis were normal. The patient's fecal occult blood test positive, and a small number of Enterobacteriaceae species was detected from the stool culture. Other pathogens were not inspected. Immunological tests were positive for antinuclear and anti-DNA antibody, and there was little or no decrease in serum complement levels. Small amounts of proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) and myeloperoxidaseantineutrophil cytoplasmic antibody (MPO-ANCA) were detected, however, these numbers were not significant of clinical value.
Gallium scintigram showed mild up-takes only in both kidneys and lungs. Computed tomography (CT) of the abdomen revealed no thickening of the intestinal wall or other abnormalities. The CT of the chest revealed localized fibrous changes in her lower lungs, presumably due to her past history of complication of interstitial pneumonia in 1989.
Colonoscopy in early October revealed that the ulcerative lesion in the patient's upper rectum had decreased in size without any change in treatment (oral prednisolone 15 mg/-day), however, a new ulcerative lesion accompanied by white fur with mucosal swelling was detected at the junction of the sigmoid and descending colon (SD junction). Pathological study (Fig. 2) revealed mild lymphoplasmacytic invasion in the microvessel walls and surrounding submucosa; however, the invasion was insufficient to support a diagnosis of active angitis because no vasodestructive lesion was seen.
The patient began conservative treatment with 40 mg/day of oral prednisolone in late October. Her neuropathy gradually improved, however, the follow-up colonoscopy in early November revealed that although the ulcer at the SD junction was healing, the punched-out ulcers in the rectum had increased in size and number. Because the steroid therapy appeared to have no effect on the ulcerative lesions, we initiated treatment with oral mesalazine (1.0 g/day), which is often prescribed for ulcerative colitis and intestinal Behcet disease, and we reduced the oral prednisolone dosage. The gastrointestinal symptoms disappeared gradually, and colonoscopy in late November revealed that the rectal ulcer was in the healing stage with partially regenerated epithelium.
The patient was discharged in late December 2001 and continues to be monitored on an outpatient basis. The SLE itself has been controlled well with treatment. She sometimes complains of mild abdominal pain and diarrhea without bloody stool, and the oral mesalazine has been increased to 4.5 g/day.
Patient 2
A 38-year-old woman with a history of SLE was admitted to our hospital in February 2004, because of persisting abdominal pain, diarrhea, and mucous bloody stool. Endoscopic examination revealed a superficial map-like ulcer in her lower rectum. Details of the clinical course are shown in Fig. 3 .
In 1981, when the patient was 15 years old, a general practitioner diagnosed SLE, on the basis of persisting fever, erythema, and positivity for antinuclear antibody and leukocyte esterase. In 1982, the patient developed complications such as thrombocytopenia and proteinuria, which improved after steroid therapy. Following the initial steroid treatment, she continued on prednisolone at 10 mg/day, and the disease condition was stabilized. In 2000, the complement titer began to decrease. In August 2002, the patient began to experience morning stiffness, and she developed proteinuria in December. During the 3-year period from 2000 through 2002, her anti-DNA antibody level increased from 2.0 IU/ml to 20.1 IU/ml. By the time she developed gastrointestinal symptoms (mild abdominal pain and diarrhea once a week) in November 2003, she was taking prednisolone at 20 mg/ day and had been taking an immunosuppressant (mizoribine 150 mg/day) for 8 months, but the increased anti-DNA antibody levels and low complement titers indicated that the treatment had not resulted in marked improvement.
At the end of January 2004, the episodes of abdominal pain and diarrhea became frequent and intense, and the patient reported mucous bloody stool. Symptomatic therapy brought no improvement, and she continued each day to have more than 10 episodes of mucous bloody diarrhea associated with abdominal cramps. She was thus admitted to our department in mid-February for detailed examination and therapy.
On the day of admission, the patient was afebrile with normal vital signs. Physical examination disclosed tenderness in the left lower abdomen without muscular defense; other findings were essentially normal. The CBC revealed mild leukocytopenia but no anemia. Inflammatory cell levels were not elevated, and the CRP test was negative, but the ESR was moderately accelerated. Urinalysis was positive for urinary protein (0.69 g/day), and the serum albumin level was mildly decreased, but the results of routine kidney function tests were normal and creatinine clearance was 102. ml/min. The patient's fecal occult blood test was negative, and the culture was positive for a small number of Enterobacteriaceae species, but negative for other pathogens including cytomegalovirus. Tests of the coagulo-fibrinolytic system revealed mild prolongation of the prothrombin time and activated partial thromboplastin time, and mild elevation of thrombomodulin, thrombin-antithrombin III complex, and D-dimer levels. Immunological tests were positive for antinuclear and anti-DNA antibodies, and the serum complement titer was markedly decreased. The results of tests for anti-cardiolipin antibody, lupus anticoagulants, PR3-ANCA, and MPO-ANCA were negative. Chest and abdominal X-ray findings and electrocardiography findings were normal.
Endoscopic examination (Fig. 4A ) revealed a map-like ulcerative lesion in the rectum between the anus and the site of peritoneal evagination (Rb to Ra). The ulcer and tissue at its periphery were biopsied, and nonspecific fibrosis, congestion, granulation, and partial lymphoplasmacytic infiltration were observed (Fig. 4B and 4C ). However, neither vasculitis nor specific deposition of immune complexes in the lesion was detected. CT of the pelvis (Fig. 5) revealed thickening of the rectal wall, a relatively high-density area in the surrounding soft tissues, and tiny air particles outside the intestinal wall, which suggested extensive pelvic inflammation with minor perforation of the ulcer.
Treatments with intravenous prednisolone (40 mg/day), antibiotic, and proton pump inhibitor as well as nutritional management by intravenous hyperalimentation were initiated. The patient's gastrointestinal symptoms were relieved dramatically within 5 days after the start of the treatment. Follow-up computed tomography in late February showed decreased rectal wall thickening and no tiny air particles. Colonoscopy on March 1 showed improvement of the rectal ulcerative lesion, and oral nutrition was started the next day. After 4 weeks of intravenous prednisolone therapy, the CBC normalized, serum complement levels recovered (C3 59 mg/dl, C4 8 mg/dl, CH50 24.8 U/ml on March 25), and immune antibody titers were decreased (anti-DNA antibody 7.4 IU/ml on March 25). An endoscopic photograph of the patient's rectum obtained 5 weeks after the start of therapy (Fig. 4D) revealed that the ulcerated area was reduced and its surface was covered by regenerated epithelium. The patient was discharged on March 30 and is being monitored on an outpatient basis. Her serum complement and immune antibody titers were normalized by the end of June 2004 (C3 66 mg/dl, C4 13 mg/dl, CH50 34.9 U/ml, anti-DNA antibody 7.4 IU/ml). toms, and lupus enteritis has been reported to be the most common cause of acute abdominal pain, accounting for up to 45% of cases (3) . Gastrointestinal vasculitis is one of the most serious complications of SLE, even though the occurrence of colonic lesions is quite rare (0.2%) (2, 3). The reason for infrequent involvement of the colon, especially the rectum, might be the rich, dual-source blood supply (3, 4) . SLE is a multiorgan disease in which many manifestations are consequences of tissue damage from vasculopathy mediated by immune complexes, and gastrointestinal vasculitis and thrombosis have been associated with SLE activity (5) .
Discussion
In SLE, circulating immune complexes involving known and unknown autoantibodies eventually cause complement activation at the site of their deposition. Activated complement factors leading to necrotizing immune vasculitides, and deposition of immune complexes can also be seen in vessels apparently unaffected by vasculitis. Vasculitic lesions can be acute and fatal when they involve the kidney, heart, lung, or gastrointestinal tract. There are no pathognomonic histopathological findings in SLE, however, pathological changes associated with gastrointestinal vasculitis typically occur in the small vessels of the intestinal wall rather than in medium-sized mesenteric arteries. Ischemic necrosis results in eventual ulceration and hemorrhage of the mucosa and submucosa (2) .
Complications patients are often referred to as "lupus colitis." Lupus colitis is classified as one of five types according to its clinical manifestations: multiple ulcers, ischemic colitis, proteinlosing enteropathy, intestinal pseudo-obstruction, or other manifestations such as cystic emphysema of the intestinal tract or complications of Crohn's disease and ulcerative colitis. The differences in clinical manifestations presumably derive from characteristics of the vasculitis such as size of the blood vessels and anatomical features (1, 6) . Lymphedema caused by obstruction of the normal flow of the lymphatics (7) or vasculitis and widespread capillary leakiness mediated by cytokines (8) are thought to be responsible for proteinloosing enteropathy. Smooth muscle dysmotility due to neurological pathology or secondary to vasculitis and autoantibodies against smooth muscle are suggested for intestinal pseudo-obstruction (9). Multiple ulcer-type lupus colitis develops relatively gradually with symptoms of lower abdominal pain or bloody stools (6) . Gross findings typically reveal (can be solitary) round or oval discrete lesions, so-called "punched-out ulcers," or irregularly shaped, deep ulcerative lesions (10, 11) . Development of vasculitis possibly involves the deposition of immune complexes formed from immunoglobulin G (IgG), immunoglobulin M (IgM), complements, and other molecules in the vascular intimae (12) . Histopathological study reveals that fibrinoid necrosis and fibrous thickening of the vascular walls as well as infiltration of inflammatory cells are observed mainly in the small arteries (13) .
A typical vasculitis pattern is difficult to prove on the basis of endoscopic biopsy specimens (12) , and neither of the present cases showed specific vasculitis or deposition of immune complexes. Comparing to criterias, ulcerative colitis (rectal ulcer type, one attack only) was under consideration as a differential diagnosis, however, neither colonoscopy nor pathological study found specific findings to be sufficient to overthrow the diagnosis.
To date, gastrointestinal complications, particularly multiple ulcerative lesions in the large intestine have been reported in 25 cases in Japan, including ours ( Table 2) . Most of these complications occurred during the active stages of SLE (in at least 16 out of the 25 cases) in relatively young patients, ranging in age from 15 to 57 years. The most dangerous complications such as perforation and fistula were observed in 9 of the 25 patients, including 4 who died.
There are several options for the management of multiple ulcer-type lupus colitis. At present, no particular treatment regimen is recommended. Corticosteroid is usually the firstchoice therapy because suppression of the inflammatory response is quick; it is expected to have an effect within 12 to 48 hours (3). However, there are many steroid-resistant cases, as shown in Fig. 6 , and perforations of the intestinal tract occurred in several of these cases after the induction of steroid therapy. Risk factors for aggravation of the ulcers are thought to be delayed healing of the ulcerative lesions and weakening of the mucosal tissues in addition to ischemic tissue damage due to locally reduced blood flow (7).
Recent reports have described successful treatment with intravenous pulse cyclophosphamide in cases of steroidresistant colonic ulcers due to intestinal valculitis (2) . Such treatment can reduce the unpleasant effects of steroid therapy, and prevent devastating complications.
The present patients had several characteristics in common. Immunological examinations revealed increased anti-DNA antibody levels and decreased complement levels at the onset of their gastrointestinal symptoms, indicating that the colonic ulcers in both cases occurred during the active stage of SLE. Increased dose of steroid therapy, a maximum of prednisolone at 40 mg/day, was sufficient to normalize the serologic markers of SLE disease activity.
The present cases differed from each other in that rectal lesions in one case progressed despite steroid treatment, but the lesions in the other case responded quickly to steroid therapy. We consider this difference to be a result of the lapse in time from the development of gastrointestinal symptoms to the initiation of steroid therapy in case 1. Abdominal pain and loose stool first appeared 4 months before the induction of additional steroid therapy in case 2. In comparison, the first abdominal symptom in case 1 was present 8 months before the start of additional steroid therapy. In addition, the patient's neuropathy (sensory disorder in the legs) and ulcerative lesions in the sigmoid colon, which preceded the therapy by 3 months and 1 month, respectively, clearly improved with steroid therapy. Our experience suggests that delay in the initiation of steroid therapy may have allowed for irreversible changes in the blood vessels for which steroid therapy might have been no longer effective.
Conclusion
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